Combating Counterfeit Pharmaceuticals Act of 2025
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, the Combating Counterfeit Pharmaceuticals Act of 2025, amends the existing Fentanyl Sanctions Act to expand its scope beyond fentanyl and opioids to cover all illicit drugs. It adds two new categories of sanctionable substances: "copy-cat ingredients" (ingredients that mimic approved drug substances but are manufactured by different processes or fall below quality standards) and "counterfeit drugs" (as defined by existing FDA law). It allows the Director of National Intelligence to delegate responsibilities under the Act. It narrows an existing waiver provision that allowed sanctions relief for access to prescription medications, limiting it to only medications on the current drug shortage list. It also makes numerous technical conforming amendments replacing "opioid" with "illicit drug" throughout the Act.
Who Benefits and How
Legitimate pharmaceutical manufacturers benefit from expanded sanctions against foreign entities producing copy-cat ingredients that undermine their products. The general public and patients benefit from stronger enforcement against counterfeit and substandard drugs entering the U.S. supply chain. U.S. national security interests are served by broader sanctions authority against illicit drug trafficking networks. The intelligence community benefits from operational flexibility through DNI delegation authority.
Who Bears the Burden and How
Foreign manufacturers of copy-cat pharmaceutical ingredients face new sanctions exposure. Foreign illicit drug trafficking organizations (beyond just opioid traffickers) now fall under the sanctions regime. Foreign entities that previously obtained waivers for prescription medication access now face a narrower waiver limited to drugs on the shortage list. The DNI and intelligence community bear implementation burdens for the expanded scope of illicit drug trafficking monitoring.
Key Provisions
- Defines "copy-cat ingredient" as an ingredient mimicking an approved drug substance but manufactured differently or of lower purity/quality (Section 2)
- Adds "counterfeit drugs" and "copy-cat ingredients" to sanctionable substance categories (Section 2)
- Broadens scope from "opioid trafficking" to "illicit drug trafficking" throughout the Act (Section 5)
- Allows DNI to delegate responsibilities under the Act (Section 3)
- Narrows sanctions waiver for prescription medications to only those on the current drug shortage list (Section 4)
- Conforming amendments to the Foreign Assistance Act (Section 5)
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Amends the Fentanyl Sanctions Act to broaden its scope from opioid-specific trafficking to all illicit drug trafficking, adds definitions for copy-cat ingredients and counterfeit drugs as sanctionable substances, allows DNI delegation, and narrows the sanctions waiver for prescription medication access to drugs on the current shortage list.
Key Policy Areas
Drug Policy, Foreign Affairs and Sanctions, National Security, Pharmaceuticals
Primary Purpose
Amends the Fentanyl Sanctions Act to broaden its scope from opioid-specific trafficking to all illicit drug trafficking, adds definitions for copy-cat ingredients and counterfeit drugs as sanctionable substances, allows DNI delegation, and narrows the sanctions waiver for prescription medication access to drugs on the current shortage list.
Policy Domains
Fentanyl Sanctions Act Amendments for Counterfeit Drug Trafficking
Identified Gains
Contextual inference, no direct clause citation- Legitimate pharmaceutical manufacturers (protection from copy-cat competitors)
- U.S. patients and public health (stronger enforcement against counterfeit drugs)
- U.S. national security apparatus (broader sanctions authority)
- Intelligence community (operational flexibility through DNI delegation)
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Foreign manufacturers of copy-cat pharmaceutical ingredients (new sanctions exposure)
- Foreign illicit drug trafficking organizations (expanded sanctions scope)
- Foreign entities seeking prescription medication waivers (narrower waiver eligibility)
- DNI and intelligence community (implementation of expanded monitoring scope)
Contextual inference, no direct clause citation
Sponsors
Tom Cotton
R-AR | Primary Sponsor
Legislative Progress
In CommitteeMr. Cotton (for himself and Mr. Ricketts) introduced the following …
Read twice and referred to the Committee on Banking, Housing, …
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Foreign illicit drug trafficking organizations, Foreign illicit drug trafficking organizations (non-opioid), U.S. patients and public health
Positive-direction: U.S. patients and public health, U.S. public health and safety interests
Negative-direction: Foreign illicit drug trafficking organizations, Foreign illicit drug trafficking organizations (non-opioid), U.S. patients needing medications not on shortage list
Director of National Intelligence and intelligence community, Office of National Drug Control Policy, U.S. sanctions enforcement (stronger enforcement posture)
Positive-direction: Director of National Intelligence and intelligence community, Office of National Drug Control Policy, U.S. sanctions enforcement (stronger enforcement posture)
Negative-direction: U.S. sanctions enforcement apparatus
Foreign entities seeking sanctions waivers for prescription medications, Foreign manufacturers of copy-cat pharmaceutical ingredients, Legitimate U.S. pharmaceutical manufacturers
Positive-direction: Legitimate U.S. pharmaceutical manufacturers
Negative-direction: Foreign entities seeking sanctions waivers for prescription medications, Foreign manufacturers of copy-cat pharmaceutical ingredients
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_director"
- → Director of National Intelligence
- "the_secretary"
- → Secretary of Health and Human Services
Key Definitions
Terms defined in this bill
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology